Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation

依杜沙班 心房颤动 医学 心脏病学 内科学 华法林 达比加群
作者
Ken Okumura,Masaharu Akao,Tetsuro Yoshida,Masahito Kawata,Osamu Okazaki,Shintaro Akashi,Kenichi Eshima,Kimihiko Tanizawa,Masayuki Fukuzawa,Takuya Hayashi,Masahiro Akishita,Gregory Y.H. Lip,Takeshi Yamashita
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:383 (18): 1735-1745 被引量:344
标识
DOI:10.1056/nejmoa2012883
摘要

BACKGROUND: Implementation of appropriate oral anticoagulant treatment for the prevention of stroke in very elderly patients with atrial fibrillation is challenging because of concerns regarding bleeding. METHODS: We conducted a phase 3, multicenter, randomized, double-blind, placebo-controlled, event-driven trial to compare a once-daily 15-mg dose of edoxaban with placebo in elderly Japanese patients (≥80 years of age) with nonvalvular atrial fibrillation who were not considered to be appropriate candidates for oral anticoagulant therapy at doses approved for stroke prevention. The primary efficacy end point was the composite of stroke or systemic embolism, and the primary safety end point was major bleeding according to the definition of the International Society on Thrombosis and Haemostasis. RESULTS: A total of 984 patients were randomly assigned in a 1:1 ratio to receive a daily dose of 15 mg of edoxaban (492 patients) or placebo (492 patients). A total of 681 patients completed the trial, and 303 discontinued (158 withdrew, 135 died, and 10 had other reasons); the numbers of patients who discontinued the trial were similar in the two groups. The annualized rate of stroke or systemic embolism was 2.3% in the edoxaban group and 6.7% in the placebo group (hazard ratio, 0.34; 95% confidence interval [CI], 0.19 to 0.61; P<0.001), and the annualized rate of major bleeding was 3.3% in the edoxaban group and 1.8% in the placebo group (hazard ratio, 1.87; 95% CI, 0.90 to 3.89; P = 0.09). There were substantially more events of gastrointestinal bleeding in the edoxaban group than in the placebo group. There was no substantial between-group difference in death from any cause (9.9% in the edoxaban group and 10.2% in the placebo group; hazard ratio, 0.97; 95% CI, 0.69 to 1.36). CONCLUSIONS: In very elderly Japanese patients with nonvalvular atrial fibrillation who were not appropriate candidates for standard doses of oral anticoagulants, a once-daily 15-mg dose of edoxaban was superior to placebo in preventing stroke or systemic embolism and did not result in a significantly higher incidence of major bleeding than placebo. (Funded by Daiichi Sankyo; ELDERCARE-AF ClinicalTrials.gov number, NCT02801669.).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
充电宝的应助被小马宝莉采纳,获得10
1秒前
1秒前
轻松的澜完成签到,获得积分10
1秒前
May发布了新的文献求助10
1秒前
2秒前
2秒前
有机化学aaa123完成签到,获得积分10
3秒前
5秒前
yang发布了新的文献求助50
5秒前
minminmin发布了新的文献求助10
6秒前
瑾瑜发布了新的文献求助10
6秒前
深情安青的应助被aniu采纳,获得10
7秒前
风吹麦浪的应助被不灵0采纳,获得10
7秒前
lzulzy完成签到,获得积分10
8秒前
9秒前
9秒前
10秒前
粗心的忆山完成签到 ,获得积分10
12秒前
12秒前
清秀冰淇淋完成签到,获得积分10
13秒前
8R60d8的应助被奶茶采纳,获得10
13秒前
定风雨完成签到 ,获得积分10
14秒前
桐桐的应助被azxi采纳,获得30
14秒前
杪春发布了新的文献求助10
15秒前
我是老大的应助被蓝天白云采纳,获得10
15秒前
CipherSage的应助被SanXing三醒采纳,获得10
17秒前
科研通AI6.4的应助被李瑞程采纳,获得10
17秒前
17秒前
科研通AI6.4的应助被积极从蕾采纳,获得10
18秒前
19秒前
66完成签到,获得积分10
19秒前
23秒前
秋风的应助被默默的含蕾采纳,获得10
24秒前
大模型的应助被不灵0采纳,获得10
25秒前
25秒前
28秒前
赘婿的应助被认真的小海豚采纳,获得10
28秒前
英姑的应助被congcong采纳,获得10
29秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183324
求助须知:如何正确求助?哪些是违规求助? 9572627
关于积分的说明 21826529
捐赠科研通 7780320
什么是DOI,文献DOI怎么找? 3433993
关于科研通互助平台的介绍 2558155
邀请新用户注册赠送积分活动 2480290